Natural killer cell phenotype and clinical response to interferon-beta therapy in multiple sclerosis
- 1 December 2011
- journal article
- research article
- Published by Elsevier in Clinical Immunology
- Vol. 141 (3) , 348-356
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Interleukin‐2/interleukin‐2 antibody therapy induces target organ natural killer cells that inhibit central nervous system inflammationAnnals of Neurology, 2010
- An IL-2 Paradox: Blocking CD25 on T Cells Induces IL-2–Driven Activation of CD56bright NK CellsThe Journal of Immunology, 2010
- Effect of Anti-CD25 Antibody Daclizumab in the Inhibition of Inflammation and Stabilization of Disease Progression in Multiple SclerosisArchives of Neurology, 2009
- Cytometric profiling in multiple sclerosis uncovers patient population structure and a reduction of CD8low cellsBrain, 2008
- T cell subset-specific susceptibility to agingClinical Immunology, 2008
- Tonsilar NK Cells Restrict B Cell Transformation by the Epstein-Barr Virus via IFN-γPLOS Pathogens, 2008
- Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-betaNeurological Sciences, 2007
- Regulatory CD56brightnatural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosisProceedings of the National Academy of Sciences, 2006
- NK CELL RECOGNITIONAnnual Review of Immunology, 2005
- MHC class I molecules and kirs in human history, health and survivalNature Reviews Immunology, 2005